Paige Announces New Data on Breast Cancer Detection System To Be Presented at San Antonio Breast Cancer Symposium
- Data from study conducted at Memorial Sloan Kettering Cancer Center illustrates potential applications of machine learning in breast cancer detection
- Results to be presented during spotlight poster discussion on December 10
NEW YORK–(BUSINESS WIRE)–Paige, a global leader in AI-based digital diagnostics, will present new data evaluating Paige Breast Alpha, a machine learning system designed to detect breast cancer in digital images of breast tissue, at the upcoming 2020 San Antonio Breast Cancer Symposium (SABCS 2020), taking place virtually December 8-11, 2020.
For pathologists reviewing breast tissue slides under the microscope, the large volume of slides can pose significant challenges for workload management and pathologist productivity. The poster, “Clinical-grade detection of breast cancer in biopsies and excisions using machine learning,” will be featured during a spotlight poster discussion, which highlights some of the most noteworthy and groundbreaking research submitted to the conference.
The poster abstract is available online and viewing details are below:
Clinical-grade detection of breast cancer in biopsies and excisions using machine learning
Authors: Hanna MG, et al.
Session: Spotlight Poster Discussion 6 | Thursday, December 10, 2020 | 3:30pm – 4:45pm CST
Poster #: PD6-03
Paige was founded in 2017 by Thomas Fuchs, Dr.Sc. and colleagues from Memorial Sloan Kettering Cancer Center (MSK). The company builds computational pathology products designed so patients and their care teams can make effective, more informed treatment decisions. With this new class of AI-based technologies positioned to drive the future of diagnostics, Paige created a platform to deliver this novel technology to pathologists to transform their workflow and increase diagnostidc confidence and productivity. Paige’s products deliver insights to pathologists and oncologists so they can arrive efficiently at more precise diagnoses for patients. Paige is the first company to receive FDA breakthrough designation for computational pathology products.
Dr. Matthew Hanna has a compensated consulting relationship with Paige. MSK has intellectual property rights and associated financial interests related to Paige by virtue of licensing agreements between MSK and Paige.
Westwicke/ICR Healthcare PR